Plain-English translation of NCT06694935 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called in people who have both type 2 diabetes and non-alcoholic fatty liver disease (when fat builds up in the liver without being caused by alcohol). Researchers want to find the right dose of this medication and understand how well it works for controlling blood sugar and improving liver health.
People with type 2 diabetes often develop fatty liver disease, and current treatments don't always address both conditions well. This trial explores whether this new treatment could help manage both problems at the same time.
You likely qualify if…
You likely don't qualify if…
You would take the medication as directed by the research team and visit the study center several times for blood tests and other measurements to check how the medication affects your blood sugar, liver health, and overall metabolism. The researchers will gradually adjust the dose and monitor you closely to find the safest and most effective amount of the medication for future studies.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Canada
Safety & dosing
Sponsor
1Globe Health Institute
Enrollment target
~52 participants
Started
January 2025
Primary completion
July 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 64 Years
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
1Globe Health Institute
1Globe Health Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.